Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14621420 | 0.82 | HSPB1 (0.48) | HSPB1KDM4ECARM1MAPTMEN1 | |
| SCHEMBL5261995 | 0.81 | HSPB1 (0.56) | HSPB1KDM4EALDH1A1MAPTSCN9A | |
| SCHEMBL23781876 | 0.80 | MAP4K4 (0.51) | HSPB1KDM4EMAP4K4CARM1MET | |
| SCHEMBL1797972 | 0.79 | HSPB1 (0.54) | HSPB1KDM4EMAPT | |
| SCHEMBL21906327 | 0.79 | HSPB1 (0.51) | HSPB1KDM4ECARM1METMAPT | |
| SCHEMBL15067206 | 0.77 | KDM4E (0.48) | KDM4EALDH1A1GLAGAACARM1 | |
| SCHEMBL29043665 | 0.76 | ALDH1A1 (0.58) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL31582715 | 0.75 | KDM4E (0.54) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL15359911 | 0.75 | KDM4E (0.54) | KDM4EALDH1A1GLAGAAMAPT | |
| SCHEMBL31371422 | 0.75 | BRD4 (0.43) | KDM4EALDH1A1GLAGAACARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135459-A1 | Substituted 7-aza-quinazoline compounds useful as p38 kinase inhibitors | DEWDNEY NOLAN J | 2007-06-14 | — | — | US | disclosed |
| US-20070135459-A1 | Substituted 7-aza-quinazoline compounds useful as p38 kinase inhibitors | DEWDNEY NOLAN J | 2007-06-14 | — | — | US | disclosed |
| US-20070135459-A1 | Substituted 7-aza-quinazoline compounds useful as p38 kinase inhibitors | DEWDNEY NOLAN J | 2007-06-14 | — | — | US | disclosed |
| US-7189731-B2 | Substituted 7-azaquinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189731-B2 | Substituted 7-azaquinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189731-B2 | Substituted 7-azaquinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1620105-B1 | (6-(PHENOXY)-PYRIDO¬3,4-D|PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS SUCH AS RHEUMATOID ARTHRITIS | HOFFMANN LA ROCHE (CH) | 2007-01-10 | — | — | EP | disclosed |
| EP-1620105-B1 | (6-(PHENOXY)-PYRIDO¬3,4-D|PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS SUCH AS RHEUMATOID ARTHRITIS | HOFFMANN LA ROCHE (CH) | 2007-01-10 | — | — | EP | disclosed |
| EP-1620105-A1 | (6-(PHENOXY)-PYRIDO[3,4-D]PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS SUCH AS RHEUMATOID ARTHRITIS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004091625-A1 | (6-(PHENOXY)-PYRIDO`3,4-D! PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORYY CONDITIONS SUCH AS RHEUMATOIS ARTRITIS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209903-A1 | Substituted 7-azaquinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135459-A1 | Substituted 7-aza-quinazoline compounds useful as p38 kinase inhibitors | MAPK7, MAPK1, MAPK8 | HSPB1 2421/4885KDM4E 924/4885ALDH1A1 3158/4885 |
| US-20040209903-A1 | Substituted 7-azaquinazoline compounds useful as p38 kinase inhibitors | MAPK1, MAPK7, MAPK6 | HSPB1 1468/4885KDM4E 1259/4885ALDH1A1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.